Mizuho Securities Remains Sidelined on Allergan (AGN) following 1Q Earnings; PT to $232

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/19/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to Mizuho Securities Remains Sidelined on Allergan (AGN) following 1Q Earnings; PT to $232

Goldman Sachs Sees Catalysts for Allergen (AGN) and Adds to Conviction Buy List

May 13, 2016 6:37 AM EDT

(Updated - May 13, 2016 8:58 AM EDT)

Goldman Sachs upgraded Allergen (NYSE: AGN) from Buy to Conviction Buy, with a price target of $275, implying upside of 27%. Following management meetings, analyst Jami Rubin has increased confidence in Allergen's underlying business, and she sees sustainable topline growth with operating margin expansion.

"Our increased confidence is based on 1) a... More

Wall Street mixed as Apple tumbles to two-year low

May 12, 2016 7:42 AM EDT

By Noel Randewich

(Reuters) - U.S. stocks ended mixed on Thursday, with gains in telecommunications and consumer staples helping make up for a tumble in Apple to a two-year low.

The S&P 500 and Dow Jones swerved between gains and losses before ending virtually flat. Up 0.90 percent, Microsoft was the largest upward force in the S&P 500.

Apple Inc (NASDAQ: AAPL), a mainstay in many portfolios, was the heaviest drag on the three major indexes, slumping 2.35 percent to $90.34, its lowest since June 2014, as worries festered about... More

Allergan plc (AGN): Incrementally Cautious - Piper Jaffray

May 11, 2016 7:46 AM EDT

Piper Jaffray analyst, David Amsellem, is cautious on Allergen (NYSE: AGN) despite bright spots in the quarter. The company needs incremental products to growth the top line leaving the path to growth murky.

AGN reported non-GAAP diluted EPS of $3.04 on revenues of $3.8B,... More